RapidAI

Golden, CO, United States All United States companies → — Founded 2011

Imaging AI Specialist Specialty-Focused AI

Emergency Medicine Neurology Radiology

Neurology AI Radiology & Imaging AI Triage & ER/ICU AI

Series C — $103M

Claim this company

Products

Rapid Enterprise Platform

RapidAI

Cardiology AI

RapidAI's Enterprise Platform offers FDA-cleared, deep clinical AI solutions that connect imaging to clinical action across the health system, integrating with EHRs and PACS for enhanced decision-making and workflow efficiency.

Rapid ICH

RapidAI

Neurology AI

Rapid ICH by RapidAI is an FDA-cleared AI software that rapidly detects and triages suspected intracranial hemorrhage on non-contrast CT scans, delivering critical insights to clinicians for faster stroke treatment decisions.

Contact for pricing

Rapid ASPECTS

RapidAI

Neurology AI

Rapid ASPECTS provides an automated, standardized ASPECTS score from non-contrast CT scans to quantify early ischemic changes and aid in determining thrombectomy eligibility for stroke patients.

Annual subscription model; pricing varies by region, hospital type, modules, and imaging modalities. starts at approximately $12,000 for a single module in the united states.

See all 3 products →

About RapidAI

RapidAI is a global leader in leveraging artificial intelligence (AI) to address life-threatening vascular and neurovascular conditions. The company specializes in developing AI-driven imaging solutions primarily for stroke, trauma, and various vascular diseases. Its advanced platform provides comprehensive tools for physicians, enabling the viewing, processing, and analysis of diverse imaging modalities, including non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion data. This technology assists clinicians in making accurate and timely diagnostic and treatment decisions for conditions such as ischemic stroke, intracranial hemorrhages, subdural hematomas, cerebral aneurysms, and pulmonary embolism.

The Rapid Enterprise™ Platform is designed to support a broad spectrum of disease states by deploying deep clinical AI. This goes beyond basic triage, allowing for the characterization, quantification, visualization, and tracking of changes over time. The platform aims to enhance confident decision-making, significantly reduce time to treatment, and ultimately improve patient outcomes. It achieves this by delivering specific, relevant, and contextual data, seamlessly integrating into existing hospital systems through PACS, EHR, and dedicated mobile applications.

RapidAI has secured numerous FDA clearances for its various modules, including those for detecting intracranial hemorrhages, large vessel occlusions, midline shift, obstructive hydrocephalus, and for aortic measurements. The company’s solutions are utilized by over 2,500 hospitals in more than 100 countries and are supported by over 700 clinical studies, underscoring its position as a clinically validated AI platform in healthcare.

Focus Areas

Neurovascular conditions Ischemic Stroke Hemorrhagic Stroke Aneurysm Aortic Disease Pulmonary Embolism Cardiac & Vascular Advanced Imaging Clinical Decision Support Radiology Workflow Optimization Enterprise Imaging Acute Assessment Longitudinal Patient Management Life Sciences

Business Intelligence

Key Investors	Vista Equity Partners, Cullom Capital, Lennertz & Co., Listwin Ventures, Vista Credit Partners
Partnerships	Amazon Web Services (AWS), Alaska Stroke Coalition
Acquisitions	EndoVantage
Technology	Rapid Enterprise™ Platform, Rapid Edge Cloud (hybrid cloud-native with on-prem capabilities), Deep Clinical AI, AI Orchestrator, Navigator Pro, Rapid Insights, Kubernetes
FDA Clearances	30 cleared products (estimated)

What Physicians Need to Know

Neurovascular & Stroke Care (Ischemic & Hemorrhagic)

RapidAI offers a comprehensive suite of AI solutions for neurovascular conditions, including ischemic stroke, hemorrhagic stroke, and aneurysms. Their technology provides AI-driven image analysis for MRI, non-contrast CT, CT angiography (CTA), and CT perfusion (CTP) scans. Key modules include Rapid LVO for Large Vessel Occlusion detection (demonstrating 98% sensitivity in studies), Rapid ICH for Intracerebral Hemorrhage, Rapid ASPECTS for automated ASPECTS scoring, and Rapid SDH for Subdural Hematoma detection. Their solutions have been instrumental in expanding the ischemic stroke treatment window from 6 to 24 hours, based on landmark clinical trials (DAWN and DEFUSE-3).

Aneurysm & Aortic Disease Management

The RapidAI platform includes modules for Aneurysm Triage & Notification, automatically detecting potential brain aneurysms and generating immediate alerts for faster diagnosis and treatment planning. Studies show RapidAI's aneurysm platform detected 46% more clinically significant growth compared to neuroradiologists alone, supporting improved longitudinal monitoring and assessment of rupture risk. They also offer Rapid Aortic solutions to find and track more aortic patients.

Pulmonary Embolism (PE) & Cardiac & Vascular

RapidAI extends its AI capabilities to Pulmonary Embolism with the PE RV/LV Triage & Notification module, dedicated to accelerating PE care pathways. Their broader Cardiac & Vascular solutions aim to improve diagnostic and treatment decisions across various vascular conditions.

Advanced Imaging & 3D Reconstruction

The Rapid platform leverages AI to generate high-quality, advanced images from various scan types, including non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. Lumina 3D by RapidAI provides automated, consistent, high-quality 3D imaging reconstructions minutes after a head and neck CTA scan, expediting diagnosis and saving significant radiology tech hours.

Clinical Decision Support (Deep Clinical AI)

RapidAI's core differentiator is its 'Deep Clinical AI,' which goes beyond simple triage and notification. It provides precise localization, visualization, characterization, quantification, and tracking of disease states over time, offering contextual, patient-specific insights. This level of detail enhances physician decision-making, supports less-experienced readers, and acts as a reliable second opinion, especially during long shifts.

Radiology Workflow Optimization & Enterprise Imaging

RapidAI's solutions are designed to integrate seamlessly into existing hospital workflows, including PACS, EHR, worklists, and reporting systems. The Rapid Mobile App provides anytime, anywhere access to results and critical patient images, enabling real-time notifications and communication among stroke teams. The platform automates image processing and analysis, reducing manual work, cognitive burden, and improving overall productivity and efficiency.

Acute Assessment & Longitudinal Patient Management

RapidAI facilitates faster and more accurate triage, transfer, and treatment decisions for acute conditions like stroke, with AI algorithms processing scans in as few as 3 minutes. For longitudinal management, their platforms, such as the Aneurysm platform, reliably track changes over time, supporting ongoing assessment and potentially enabling earlier interventions.

Life Sciences & Research

RapidAI's technology is utilized in patient care, research, and clinical trials. Their solutions have been foundational in landmark studies that shaped stroke treatment guidelines, demonstrating a commitment to advancing medical knowledge and patient outcomes.

Physician Tip

For physicians, RapidAI offers a powerful assistant that significantly enhances diagnostic speed and accuracy, particularly in time-critical conditions like stroke. Leverage the 'Deep Clinical AI' for contextual, patient-specific insights that go beyond basic alerts, aiding in complex decision-making and potentially identifying anomalies the human eye might miss. Utilize the mobile app for real-time access to critical imaging and streamlined communication with care teams, improving workflow efficiency and reducing burnout. The platform's ability to standardize care and reduce interpretation variability can be particularly beneficial for ensuring consistent, high-quality patient management across your institution. Trust in the clinically validated and FDA-cleared nature of the solutions, which are backed by extensive research and have influenced national treatment guidelines.

RapidAI's Enterprise Platform is designed for seamless integration with existing hospital infrastructure, including PACS, EHR, worklists, and reporting systems, ensuring a unified experience without adding another layer of complexity. Powered by a unique edge-to-cloud architecture (Rapid Edge Cloud), it offers high performance, continuous uptime, enterprise-grade security, and scalability across multi-site health systems. This robust integration capability ensures that AI-driven insights are embedded directly into clinical workflows, facilitating care coordination across various departments like ED, radiology, neurology, cardiology, and interventional teams.

At a glance

Founded 2011

HQ Golden, CO, United States · United States

Team size 267

CEO Karim Karti

Funding Series C — $103M

FDA clearances 30 (estimated)

Products 3

Products by RapidAI

3 products in the directory

Rapid Enterprise Platform

RapidAI

Cardiology AI

Rapid ICH

RapidAI

Neurology AI

Contact for pricing

Rapid ASPECTS

RapidAI

Neurology AI

Rapid ASPECTS provides an automated, standardized ASPECTS score from non-contrast CT scans to quantify early ischemic changes and aid in determining thrombectomy eligibility for stroke patients.

Annual subscription model; pricing varies by region, hospital type, modules, and imaging modalities. starts at approximately $12,000 for a single module in the united states.

What the Web Says

RapidAI develops AI-driven imaging solutions primarily for stroke, trauma, and vascular conditions, aiming to expedite diagnosis and treatment decisions. The platform analyzes brain scans and integrates with hospital systems, providing results within minutes. While the product is generally well-regarded for its speed and accuracy in stroke detection, employee reviews indicate significant concerns regarding company culture and management.

Overall: Mixed

Strengths

AI-driven platform expedites diagnosis and treatment decisions for stroke and vascular conditions.
Tools analyze brain scans (CT, MRI) and provide results within minutes.
Software's detection is accurate for intracranial hemorrhage, LVO, and CT perfusion, especially with good quality exams.
Helps focus interpretation for radiologists and is liked by neuro stroke teams.
Offers real-time notifications, access to results and images on mobile devices, and care coordination features.
Exciting technology with the potential to improve acute stroke care.

Limitations

Significant negative feedback regarding executive team and management, with claims of a horrible executive team and mental abuse.
Toxic sales culture and micromanagement reported by sales representatives.
High turnover within the executive team.
Lack of evidence on the effects of RapidAI on important clinical outcomes like patient harms, mortality, and quality of life.
Cost-effectiveness of RapidAI for stroke detection is currently unknown.
Mobile app can be glitchy and difficult to log in through.

Based on reviews from: Indeed.com, Elion, NCBI Bookshelf, Zippia, Slashdot, SourceForge, Reddit, Apple App Store, SoftFinders, Working Nomads

Last updated: 2026-07-18

Videos

News, demos, and interviews about RapidAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for RapidAI →

View all on YouTube

Press & Coverage

RapidAI Press Releases

RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts

RapidAI announced that 28 scientific abstracts, spanning aneurysm monitoring, ischemic stroke detection, advanced imaging visualization, and radiology workflow optimization, were accepted at the International Stroke Conference (ISC) 2026.

2026-02

RapidAI Press Releases

RapidAI and AWS Strengthen Relationship: Accelerate Global Deployment of Deep Clinical AI

RapidAI and Amazon Web Services (AWS) announced a strengthened collaboration to accelerate the global adoption and scalability of deep clinical AI in healthcare, focusing on co-development and go-to-market alignment.

2025-12

RapidAI Press Releases

RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances

RapidAI announced U.S. Food and Drug Administration (FDA) clearance for five new imaging modules: Rapid DeltaFuseu2122, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement, significantly expanding the Rapid Enterpriseu2122 Platform.

2025-11

RapidAI Press Releases

RapidAI Earns FDA Clearance for Rapid Aortic, Bringing AI-Driven Aortic Measurements and Surveillance to Care Teams

RapidAI announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution for acute assessment and longitudinal management of aortic disease.

2025-11

RapidAI Press Releases

RapidAI and Health Holdings Company Partner to Bring Deep Clinical AI To Saudi Arabia

RapidAI announced a strategic partnership and co-development with Saudi Health Holdings Company (HHC) to serve as HHC's enterprise provider of deep clinical AI across its network of hospitals and clinics.

2025-11

Vista Equity Partners

RapidAI Announces $75 Million Growth Investment Led by Vista Credit Partners

RapidAI announced $75 million in Series C funding led by Vista Credit Partners, intended to fuel continued innovation of its advanced clinical decision and workflow support technology and expand its leadership in clinical AI solutions.

2023-07

Stroke: Vascular and Interventional Neurology

RapidAI Compared With Human Readers of Acute Stroke Imaging for Detection of Intracranial Vessel Occlusion

This article discusses a study comparing RapidAI with human readers for detecting intracranial vessel occlusion in acute stroke imaging, highlighting the use of LR graphs for simultaneous comparison of positive and negative likelihood ratios.

2024-01

RapidAI Blog

DUEL Study published in AJNR: Real-world data demonstrates superior performance for RapidAI in LVO detection

The DUEL study, published in AJNR, demonstrated RapidAI's superior performance in detecting large vessel occlusions compared to Viz.ai, emphasizing the importance of real-world validation.

2026-07

Frequently Asked Questions

How does RapidAI enhance the assessment and treatment of acute neurovascular conditions like ischemic and hemorrhagic stroke?

RapidAI utilizes AI to rapidly analyze CT and MRI images for stroke, identifying critical findings such as large vessel occlusions (LVOs), core infarct, and various types of intracranial hemorrhages (ICH, SDH, SAH). This accelerates diagnosis, streamlines workflow, and empowers clinicians to make faster, more informed treatment decisions, ultimately improving patient outcomes.

Beyond stroke, what other cardiac, vascular, and pulmonary conditions does RapidAI's platform support, and how does it integrate with existing imaging infrastructure?

RapidAI has expanded its platform to offer solutions for conditions including pulmonary embolism (PE), aortic disease, and cerebral aneurysms. The platform seamlessly integrates with existing hospital systems like PACS, EHR, and mobile applications, providing a unified approach to AI-powered analysis and insights across multiple acute conditions.

What specific features does RapidAI offer for clinical decision support and radiology workflow optimization, particularly for acute assessments?

RapidAI provides automated alerts, quantitative measurements (e.g., hematoma volume, ASPECTS score, aortic measurements), and advanced visualizations like 3D reconstructions to support precise clinical decision-making. It optimizes radiology workflow by prioritizing critical cases, reducing manual tasks, and enabling rapid, secure communication among care teams through mobile and web applications.

How does RapidAI ensure data security, patient privacy, and regulatory compliance (e.g., FDA, HIPAA) for its AI-powered solutions?

RapidAI adheres to stringent information security standards, employing data encryption (AES-256), real-time monitoring, and role-based access controls to safeguard patient data. The platform is HIPAA and GDPR compliant, ISO 13485, ISO 27001, ISO 27701, and SOC2 Type 1 certified, with its products holding necessary FDA clearances for their intended clinical uses.

What is RapidAI's approach to pricing, customer support, and partnerships, and what is the company's overall stability in the healthcare AI market?

RapidAI typically offers subscription-based pricing, customized to institution size, required modules, and deployment scale, with pricing generally not publicly listed. They provide comprehensive 24/7 live customer support, including implementation and ongoing technical assistance. With products used in over 2,200 hospitals across more than 100 countries and strategic partnerships with major technology and distribution networks, RapidAI demonstrates strong market presence and stability as a leader in clinical AI.

Can RapidAI's platform be utilized for longitudinal patient management or life sciences research beyond acute assessment?

Yes, RapidAI's deep clinical AI extends beyond acute assessment to support longitudinal patient management by characterizing, quantifying, visualizing, and tracking disease changes over time. The platform and its rich dataset are also valuable for life sciences, accelerating research, supporting clinical trials, and generating real-world evidence, as evidenced by its use in influential stroke trials.

Related Companies

Suggest an Edit →